These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 39189472)

  • 1. Prognostic impact of body composition in hepatocellular carcinoma patients with immunotherapy.
    Zhang L; Li X; Wang K; Wu M; Liu W; Wang W
    Ann Med; 2024 Dec; 56(1):2395062. PubMed ID: 39189472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of baseline body composition on prognostic outcomes in urological malignancies treated with immunotherapy: a pooled analysis of 10 retrospective studies.
    Ma W; Shi Q; Zhang L; Qiu Z; Kuang T; Zhao K; Wang W
    BMC Cancer; 2024 Jul; 24(1):830. PubMed ID: 38992606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Body composition predicts prognosis of hepatocellular carcinoma patients undergoing immune checkpoint inhibitors.
    Xiong B; Fu B; Wu Y; Gao F; Hou C
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11607-11617. PubMed ID: 37400572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of body composition on survival outcomes in melanoma patients receiving immunotherapy.
    Kuang T; Zhang L; Qiu Z; Zhang Y; Wang W
    Front Immunol; 2023; 14():1261202. PubMed ID: 38077332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive sarcopenia and myosteatosis predict prognosis of advanced HCC patients treated with immune checkpoint inhibitors.
    Liu M; Jin Q; Wang H; Li Y
    Front Immunol; 2024; 15():1396927. PubMed ID: 38690276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Impact of Sarcopenia on Clinical Outcomes in Malignancies Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Li S; Wang T; Tong G; Li X; You D; Cong M
    Front Oncol; 2021; 11():726257. PubMed ID: 34513704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential predictors for survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: A meta-analysis.
    Xu H; Cao D; Zheng Y; Zhou D; Chen X; Lei J; Ge W; Xu X
    Int Immunopharmacol; 2021 Nov; 100():108135. PubMed ID: 34530205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies.
    Kobayashi T; Kawai H; Nakano O; Abe S; Kamimura H; Sakamaki A; Kamimura K; Tsuchiya A; Takamura M; Yamagiwa S; Terai S
    BMC Cancer; 2018 Jul; 18(1):756. PubMed ID: 30041616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a meta-analysis.
    Takenaka Y; Oya R; Takemoto N; Inohara H
    J Cachexia Sarcopenia Muscle; 2021 Oct; 12(5):1122-1135. PubMed ID: 34337889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
    Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
    BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Creatinine-to-cystatin C ratio and body composition predict response to PD-1 inhibitors-based combination treatment in metastatic gastric cancer.
    Ji H; Liu B; Jin P; Li Y; Cui L; Jin S; Wu J; Shan Y; Zhang Z; Ming J; Zhang L; Du C
    Front Immunol; 2024; 15():1364728. PubMed ID: 38665913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective sudies.
    Zhang L; Feng J; Kuang T; Chai D; Qiu Z; Deng W; Dong K; Zhao K; Wang W
    Int Immunopharmacol; 2023 May; 118():110019. PubMed ID: 36933492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Sarcopenia and intramuscular fat deposition are associated with poor survival in Indonesian patients with hepatocellular carcinoma: a retrospective study".
    Mardian Y; Yano Y; Ratnasari N; Choridah L; Wasityastuti W; Setyawan NH; Hayashi Y
    BMC Gastroenterol; 2019 Dec; 19(1):229. PubMed ID: 31888500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of computed tomography-derived body composition to determine the prognosis of patients with primary liver cancer treated with immune checkpoint inhibitors: a retrospective cohort study.
    Xiao LS; Li RN; Cui H; Hong C; Huang CY; Li QM; Hu CY; Dong ZY; Zhu HB; Liu L
    BMC Cancer; 2022 Jul; 22(1):737. PubMed ID: 35794525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
    Xu S; Lai R; Zhao Q; Zhao P; Zhao R; Guo Z
    Front Immunol; 2021; 12():794099. PubMed ID: 34950153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
    Jácome AA; Castro ACG; Vasconcelos JPS; Silva MHCR; Lessa MAO; Moraes ED; Andrade AC; Lima FMT; Farias JPF; Gil RA; Prolla G; Garicochea B
    JAMA Netw Open; 2021 Dec; 4(12):e2136128. PubMed ID: 34870682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors.
    Martini DJ; Shabto JM; Goyal S; Liu Y; Olsen TA; Evans ST; Magod BL; Ravindranathan D; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Joshi SS; Kissick HT; Ogan KE; Harris WB; Kucuk O; Carthon BC; Master VA; Bilen MA
    Oncologist; 2021 Dec; 26(12):1017-1025. PubMed ID: 34342095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma.
    Fujiwara N; Nakagawa H; Kudo Y; Tateishi R; Taguri M; Watadani T; Nakagomi R; Kondo M; Nakatsuka T; Minami T; Sato M; Uchino K; Enooku K; Kondo Y; Asaoka Y; Tanaka Y; Ohtomo K; Shiina S; Koike K
    J Hepatol; 2015 Jul; 63(1):131-40. PubMed ID: 25724366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody.
    Akce M; Liu Y; Zakka K; Martini DJ; Draper A; Alese OB; Shaib WL; Wu C; Wedd JP; Sellers MT; Bilen MA; El-Rayes BF
    Am J Clin Oncol; 2021 Feb; 44(2):74-81. PubMed ID: 33350681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma -CLEAP 004 study.
    Yang CX; Pan YX; Ye F; Zhu XD; Xue J; Li X; Yuan ZG; Zhang L; Xu L; Chen YJ; Wang NY; Sun HC; Liu XF;
    Front Immunol; 2024; 15():1310239. PubMed ID: 38711515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.